Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

NCT00070252 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Inflammatory Breast Carcinoma
Male Breast Carcinoma
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions

DRUG: Capecitabine
DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Tipifarnib

Sponsor

National Cancer Institute (NCI)